The Chris Wolfe Podcast: AREDS 1, 2 and 3 ...? W/ Dr. Tiarnan Keenan

episode

EyeCode Media not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from EyeCode Media

The Chris Wolfe Podcast:Your AMD Technology Isn’t the Problem—Your System Is 20 min · 21 Sep 2026

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026

The Chris Wolfe Podcast: All Things Caratenoids w/ Kirsten Ormsby 56 min · 18 May 2026

All episodes from EyeCode Media →

Report any issue

Source

Recorded07 Jul 2025

Publisherfeed.podbean.com ↗

Handlerec:9097839

Show notes

In this conversation, Dr. Tiernan Keenan discusses his research on macular degeneration, particularly focusing on the AREDS studies and the upcoming AREDS 3. He shares insights on the effectiveness of supplements in slowing the progression of geographic atrophy and the design considerations for future studies. The discussion also delves into the role of AI in ophthalmology, its potential to enhance clinical decision-making, and the challenges of implementing AI in healthcare. Dr. Keenan emphasizes the importance of understanding the diverse phenotypes of macular degeneration across different populations and the need for more research in this area. -------------------- For our listeners, use the code 'EYECODEMEDIA22' for 10% off at check out for our Premiere Billing & Coding bundle or our EyeCode Billing & Coding course. Sharpen your billing and coding skills today and leave no money on the table! [email protected] https://coopervision.com/our-company/news-center/press-release/coopervision-and-aoa-join-forces-launch-myopia-collective Go to MacuHealth.com and use the coupon code PODCAST2024 at checkout for special discounts Show Sponsors: CooperVision MacuHealth

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.